iSpecimen (ISPC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
4 Sep, 2026Executive summary
Special Meeting scheduled for October 9, 2026, to address key corporate actions and proposals.
Stockholders will vote on five major proposals, including share issuances, a reverse stock split, future financing, an asset acquisition, and potential adjournment.
Board recommends voting in favor of all proposals to support strategic flexibility and compliance with Nasdaq rules.
Voting matters and shareholder proposals
Proposal 1: Approve issuance of shares exceeding 19.99% of outstanding stock under a May 2026 Securities Purchase Agreement, including anti-dilution and MFN provisions.
Proposal 2: Approve a reverse stock split at a ratio between 1:10 and 1:100, at the Board's discretion, to maintain Nasdaq listing compliance.
Proposal 3: Approve issuance of shares for future convertible or equity-linked securities with up to an 80% discount from VWAP, within 12 months of approval.
Proposal 4: Approve acquisition of AI assets from Foldlab AI Ltd. for $2M cash and $2.5M in stock, with shares subject to a five-year escrow and lock-up.
Proposal 5: Approve adjournment of the meeting if more time is needed to solicit votes for the above proposals.
Board of directors and corporate governance
Board is divided into three classes with staggered three-year terms, making removal of management more difficult.
Board can fill vacancies and amend bylaws without stockholder approval.
No cumulative voting for directors; special meetings can be called by the Board or by stockholders holding at least 15% of voting power.
Latest events from iSpecimen
- Revenue fell 83% and net loss widened, raising substantial doubt about going concern status.ISPC
Q2 2026 - Raising up to $5M via best-efforts offering to fund operations, marketing, and platform growth.ISPC
Registration filing - Biospecimen marketplace seeks up to $4M via Nasdaq offering amid ongoing losses and liquidity risks.ISPC
Registration filing - Best-efforts $4M offering targets biospecimen marketplace growth amid ongoing losses and risks.ISPC
Registration filing - Biospecimen marketplace raises $2.5M in private placement; large resale may impact share price.ISPC
Registration filing - Key votes include director election, auditor ratification, and a new stock incentive plan.ISPC
Proxy filing - Q1 2026 revenue plunged 85% and net loss deepened, raising going concern risks.ISPC
Q1 2026 - Meeting adjourned without business due to lack of quorum; reconvening details to follow.ISPC
AGM 2026 - 2025 revenue fell 79% to $1.93M, net loss improved to $10.49M, but going concern risks persist.ISPC
Q4 2025